Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin[®] in Diffuse Large B Cell Lymphoma
Oslo, Norway, 1 December 2020 Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin[®] ([177]Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT). Eighteen DLBCL patients were enrolled into the trial at clinical trial sites in the US and Europe and were dosed with three escalating treatment doses of Betalutin[®] (10MBq/kg, 15MBq/kg and 20MBq/kg). A preliminary data readout is expected in H1’